Brian Henick, MD
On the web
Overview
Dr. Henick is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract. As the Director of the HICCC Phase I Unit and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Dr. Henick’s clinical care and research are aligned to improve the effectiveness of, and limit side effects from, emerging cancer treatments. These efforts entail clinical trials that Dr. Henick has written and leads to study novel therapeutic approaches and to reduce steroid dependence among patients experiencing adverse events from immunotherapy.
Areas of Expertise / Conditions Treated
- Immunotherapy
- Lung Cancer
- Mesothelioma
- Thoracic Cancer
- Thoracic Lung Cases
- Thoracic Oncology
Academic Appointments
- Assistant Professor of Medicine at CUMC
Administrative Titles
- Director of HICCC Phase I Program at CUMC
- Director of Translational Research in Upper-Aerodigestive Malignancies in Medical Oncology at CUMC
- Director of Phase I Strategy at NYP-Columbia Sphere
- Medical Director of ARIC at NYPH Milstein Hospital
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Gender
- Male
Schedule an Appointment
Virtual Visits/Telehealth
Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
Insurance Accepted
Aetna
- Aetna Signature Administrators
- EPO
- HMO
- Medicare Managed Care
- NY Signature
- POS
- PPO
- Student Health
Affinity Health Plan
- Essential Plan
- Medicaid Managed Care
Amida Care
- Special Needs
Cigna
- EPO
- Great West (National)
- HMO
- Medicare Managed Care
- POS
- PPO
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicaid Managed Care
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross/Blue Shield
- EPO
- HMO
- Medicare Managed Care
- PPO
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
Fidelis Care
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicaid Managed Care
- Medicare Managed Care
Healthspring (Cigna Medicare)
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare (National)
- MagnaCare
Medicare
- Railroad
- Traditional Medicare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- HMO
- Medicaid Managed Care
RiverSpring
- Special Needs
UnitedHealthcare
- Compass (Exchange)
- Empire Plan
- HMO
- Medicaid (Community Plan)
- Medicare Managed Care
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
VNSNY CHOICE
- Medicare Managed Care
- SelectHealth
- Special Needs
WellCare
- Medicaid Managed Care
- Medicare Managed Care
World Trade Center Health Plan
- World Trade Center Health Plan
Credentials & Experience
Education & Training
- New Jersey Medical School
- Internship: Yale New Haven Hospital
- Residency: Yale New Haven Hospital
- Fellowship: Yale New Haven Hospital
Board Certifications
- Internal Medicine
Honors & Awards
Gold Humanism Honor Society (2011)
CCF/ASCO Young Investigator Award (2017)
SITC Sparkathon (2017-18)
CCF/ASCO Merit Award (2018)
ASCO Journals Editorial Fellowship (2018)
Research
Collaborating with several laboratories at the HICCC, Dr. Henick is developing personalized blood- and imaging-based biomarkers to guide precision cancer therapy, and to leverage cutting-edge model systems to test and enhance novel treatment approaches. A key interest has been in ensuring that patients across all backgrounds and socioeconomic groups are represented and poised to benefit from the therapies he develops.
Dr. Henick has presented his work at national conferences such as ASCO and AACR. He was inducted into the Gold Humanism Honor Society, received research awards from the EGFR Resisters, Conquer Cancer Foundation/ASCO, and Robert A Winn Diversity in Clinical Trials program, and was selected to the SITC Sparkathon and IASLC Academy. He was a Top Reviewer for the Journal of Clinical Oncology, Precision Oncology, where he was the inaugural Editorial Fellow and currently serves on the editorial board.
Dr. Henick was selected to participate in the ASCO Leadership Development Program and holds several leadership roles in oncology, including serving on the Scientific Planning Committee for the ASCO Annual Meeting, the Clinical Trial Committee of the Alliance for Support and Prevention of Immune-Related Adverse Events (ASPIRE), Steering Committee of AACR Project GENIE, Translational Medicine Committee of Lung-MAP, and NRG champion for the SWOG 2302 Phase III PRAGMATICA Lung study.
